::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

IMPORTANCE OF N- ACETYLCYSTEINE IN INHIBITION OF CONTRAST INDUCED NEPHROPATHY

AUTHORS:

Dr Kainat Akhtar, Dr Muhammad Nouman Iqbal, Dr Noman Yousaf

ABSTRACT:

Aim: To determine the role of N-acetylcysteine in the prevention of Contrast induced nephropathy in high-risk patients undergoing coronary angiography Study design: A Retrospective, observational study. Place and Duration: In the Nephrology and Cardiology department of Mayo Hospital Lahore for one-year duration from March 2019 to March 2020. Methodology: Medical records of 120 patients, both sex and age> 30 years, undergoing coronary angiography were reviewed. All patients were divided into two groups. Group A received N-acetylcysteine and patients in group B did not receive N-acetylcysteine. Acute contrast induced nephropathy was defined as an increase in serum creatinine of at least 0.5 mg / dL from baseline up to 48 hours after contrast medium administration. All data was collected on a pre-designed proforma. Age was compared between the two groups using an independent t-test, and the remaining parameters were analyzed using the Chi-square test. Results: There was a statistically significant difference between the two groups (group without N-acetylsysteine 17% and N-acetylcysteine group 3%, p = 0.029). Conclusion: Iopromidol, a low osmolality non-ionic contrast agent, can induce acute contrast induced nephropathy in high-risk patients, which can be prevented by prophylactic oral administration of the antioxidant N-acetylcysteine, keeping all patients well hydrated / euvolemic. Key words: contrast induced nephropathy, N-acetylcysteine, Iopromidol.